Patents by Inventor Ehsan Ghorani

Ehsan Ghorani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250257141
    Abstract: The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.
    Type: Application
    Filed: April 26, 2023
    Publication date: August 14, 2025
    Inventors: Maria Amann, Vaios Karanikas, Gabriel Schnetzler, Kane Andrew Foster, Ehsan Ghorani, Sergio Quezada, Chen Qing
  • Publication number: 20230158073
    Abstract: The present invention provides an engineered T cell for use in a method of treatment of a proliferative disorder, wherein the engineered T cell has modulated expression of one or more genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3. Further provided are activity modulators of one or more proteins encoded by genes selected from SIT1, SAMSN1, SIRPG, CD7, CD82, FCRL3, IL1RAP, FURIN, STOM, AXL, E2F1, C5ORF30, CLDND1, COTL1, DUSP4, EPHA1, FABP5, GFI1, ITM2A, PARK7, PECAM1, PHLDA1, RAB27A, RBPJ, RGS1, RGS2, RNASEH2A, SUV39H1, and TNIP3 for use in a method of enhancing immunotherapy in a subject having a proliferative disorder. Also provided are related methods of treatment employing the engineered T cell and/or inhibitor.
    Type: Application
    Filed: April 16, 2021
    Publication date: May 25, 2023
    Applicant: Cancer Research Technology Limited
    Inventors: Sergio Quezada, Karl Peggs, Charles Swanton, Ehsan Ghorani, James Reading, Felipe Galvez-Cancino, Despoina Karagianni